adequate first line drug therapy for diabetes (McCullough, 2019). This medication increases peripheral glucose uptake and insulin sensitivity, decrease hepatic glucose production, and decreases intestinal absorption (Woo & Robinson, 2015). Metformin also has a favorable impact on lipids due to the actions it takes in the liver which would be another benefit to the patient. 50 to 60% of the medication is absorbed after oral ingestion depending on whether the patient is taking extended or immediate release. Food can also alter the absorption of the medication. Plasma half-life of metformin is 6.2 hours and 17.6 hours in the blood and is excreted through the urine. Two primary contraindications noted in the use of metformin are renal disease/impairment and metabolic acidosis. Patients
with a GFR higher than 30ml/min should refrain from taking metformin (Woo & Robinson, 2015). There is also a low risk for lactic acidosis in patient taking metformin, particularly with the use of IV contrast which is why patients who receive IV contrast should not take metformin 48 post administration and until creatine is back to normal. (Woo & Robinson, 2015). What health maintenance or preventive education is important for this client based on your choice medication/treatment ? The patient should be educated on the side effects including abdominal bloating, N/V/D, and a possible metallic taste. These side effects typically resolve 2 weeks after initiation of therapy (Woo & Robinson, 2015). Additionally, with the use of Coumadin, it is advised to limit foods in vitamin K.
- Fall '16
- Metabolic Syndrome, Insulin resistance